Salute e Benessere

Philips delivers strong order intake growth in the second quarter, margin…

Second-quarter highlightsGroup sales amounted to EUR 4.5 billion, with comparable sales growth of 2%Comparable order intake increased by 9%Income from operations EUR 816 million, including EUR 538 million insurance income*)Adjusted EBITA margin increased to 11.1% of salesOperating cash inflow of EUR 89 million, with a free cash outflow of EUR 64 million Roy Jakobs, CEO of Royal Philips:“I am encouraged by our return to order intake growth this quarter, primarily driven by...
Nasdaq GlobeNewswire
29/07/2024

ALZHEIMER'S DISEASE BLOOD TESTS COULD IMPROVE DIAGNOSIS IN PRIMARY CARE, SPEED…

Dementia is often underdiagnosed—and if it is diagnosed by a clinician, many people nonetheless are unaware or uninformed of their diagnosis, according to the 2024 Alzheimer's Disease Facts and Figures report. Blood tests for Alzheimer's are demonstrating in research that they could significantly improve a clinician's accuracy and confidence, provide greater accessibility and a platform for enhanced communication. Dementia is often underdiagnosed—and if it is diagnosed by a clinician, many...
PR Newswire
28/07/2024

Innocan Pharma Submits Investigational New Animal Drug Application to FDA's…

The Company further announced that following the assessment of LPT-CBD's scientific package, the CVM recognized Innocan's contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024. Innocan's LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and...
PR Newswire
26/07/2024

EssilorLuxottica: Publication of the 2024 Interim Financial Report

Publication of the 2024 Interim Financial Report Paris, France(July 26, 2024 – 6:30 pm)– The Board of Directors of EssilorLuxottica met on July 25, 2024 to approve the condensed consolidated interim financial statements for the six-month period ended June 30, 2024.EssilorLuxottica's 2024 Interim Financial Report has been published today. The Interim Financial Report comprises the First-half 2024 Management Report, the Condensed Consolidated Interim Financial Statements, the...
Nasdaq GlobeNewswire
26/07/2024

Calliditas partner STADA receives European Commission decision for full approval…

"This is an important event for patients suffering from IgAN in Europe as Kinpeygo represents the first ever fully approved medication for this rare kidney disease. The long-term confirmatory trial met its eGFR endpoint with high statistical significance and we are delighted that the European Commission has granted a full approval for the broader population" said Renee Aguiar-Lucander, CEO. "This is an important event for patients suffering from IgAN inEuropeas Kinpeygo represents…
PR Newswire
26/07/2024

Junshi Biosciences Announces Positive Opinion from the European Medicines…

® ). The CHMP recommends approval for toripalimab for two indications:Toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC);Toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (ESCC). The...
Nasdaq GlobeNewswire
26/07/2024

Genomics Personalized Health Market to reach US$ 33 Billion by 2034, Driven by…

The genomics personalized health market is rapidly evolving, fueled by cutting-edge technological advancements and an increasing focus on individualized healthcare. One of the key drivers of this market is the advent of next-generation sequencing (NGS) technologies, which have drastically reduced the cost and time required for sequencing the human genome. The genomics personalized health market is rapidly evolving, fueled by cutting-edge technological advancements and an increasing focus on...
PR Newswire
26/07/2024

Endometriosis Treatment Market to Surge to US$ 3.1 Billion by 2034: Innovations…

Hormone therapies such as GnRH agonists and antagonists, aromatase inhibitors, and other hormonal medicines, are crucial in controlling endometriosis-related pain. Newer medications, such as GnRH antagonists like Elagolix and Letrozole, have showed promise, especially in terms of pain relief and fertility outcomes. Hormone therapies such as GnRH agonists and antagonists, aromatase inhibitors, and other hormonal medicines, are crucial in controlling endometriosis-related pain. Newer…
PR Newswire
26/07/2024

Cell Isolation/Separation Market worth $8.4 billion by 2029 driven by Growing…

Browse in-depth TOC on "Cell Isolation Market" Browse in-depth TOC on "Cell Isolation Market" 456 - Tables 62 - Figures 475 - Pages DANAHER CORPORATION (US): Leader in Cell Separation and Analysis Danaher Corporation emerged as a leader in the cell separation and analysis market due to its advanced technology, including greater automation and precise instrumentation. The company excels in improving cell separation reliability and efficiency, enabling researchers to...
PR Newswire
26/07/2024

Specialty Enzymes Market to Surpass USD 10.4 Billion by 2034, Growing at a 6.4%…

Enzymes are proteins that selectively catalyze chemical reactions, playing crucial roles in essential life processes such as digestion, respiration, and metabolism. The specialty enzymes market is expanding due to the rising demand for effective biocatalysts in pharmaceuticals and diagnostics, which drives innovation. Biotechnology and genetic engineering advancements have enabled the development of more efficient and specific enzymes, broadening their application scope. Enzymes are proteins...
PR Newswire
26/07/2024

Home Bedding Market to reach 145.95 Bn at a CAGR of 6.06 percent by 2030- Says…

Key Offerings Key Offerings Rise of Sleep-Enhancing Technology to Create Growth Opportunities Smart mattresses and bedding systems are now equipped with built-in sensors that monitor sleep patterns, heart rate, and body movements providing users with customized recommendations and insights. For instance, the Sleep Number 360 smart bed utilizes SleepIQ technology to make real-time adjustments and track sleep, benefiting a user base of over 12 million people. Smart pillows such as the...
PR Newswire
26/07/2024

Pharmerging Market Set to Hit USD 7.1 Billion by 2034, Driven by Surge in Demand…

The pharmerging market, comprises of nations such as Brazil, Russia, India, and China (BRIC) and other rapidly emerging economies, these have dynamic environment with multiple opportunities and challenges. These countries account for 40% of the world's population, with a growing middle class and an increasing prevalence of chronic diseases, driving demand for pharmaceuticals. The rapid growth in healthcare expenditures in these markets contrasts sharply with the relatively sluggish growth in G7…
PR Newswire
26/07/2024

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as…

Dr. Jason Yang, CEO, President of R&D and Executive Director of the Board at CStone, said, "We are extremely excited by today's announcement, which represents a major milestone in CStone's journey towards becoming a leading global company dedicated to eradicating cancer. Sugemalimab has not only become CStone's first independently-developed product to receive overseas marketing authorization but it is also the world's first anti-PD-L1 mAb to receive regulatory approval in Europe in…
PR Newswire
26/07/2024

Eisai will seek re-examination of CHMP opinion för lecanemab

A formal request for re-examination allows the applicant a 60-day period to provide the CHMP with the grounds for the re-examination request. The CHMP, led by new rapporteurs, will have 60 days to respond. A formal request for re-examination allows the applicant a 60-day period to provide the CHMP with the grounds for the re-examination request. The CHMP, led by new rapporteurs, will have 60 days to respond. Lecanemab is already approved inthe United States,Japan,China,South Korea...
PR Newswire
26/07/2024

GENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) for Ipsen's Iqirvo® (elafibranor) for the treatment of Primary Biliary Cholangitis...
Nasdaq GlobeNewswire
26/07/2024

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the…

TOKYO and CAMBRIDGE, Mass., July26, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated...
Nasdaq GlobeNewswire
26/07/2024

CHMP has adopted a negative opinion on lecanemab for the EU

Eisai is responsible for the clinical development, applications for market approval and commercialization of lecanemab for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region, pending European approval, and currently Eisai and BioArctic are preparing for a joint commercialization in the region. Eisai is responsible for the clinical development, applications for market approval and commercialization of lecanemab for Alzheimer's disease. BioArctic has…
PR Newswire
26/07/2024

Medical Oxygen Concentrators Market to Reach USD 7.1 Billion by 2034, Growing at…

The medical oxygen concentrator is one form of medical equipment used to provide oxygen to people with breathing-related illnesses. The respiratory mechanisms and metabolism of living things depend heavily on oxygen. An oxygen concentrator is frequently necessary for those with low blood oxygen concentrations to restore oxygen levels. The medical oxygen concentrator is one form of medical equipment used to provide oxygen to people with breathing-related illnesses. The respiratory mechanisms…
PR Newswire
26/07/2024

Piramal Pharma Limited Announces Consolidated Results for Q1FY25

Key Highlights for Q1FY25 Key Highlights for Q1FY25 Nandini Piramal, Chairperson, Piramal Pharma Limited,said, " We have had a good start to the financial year with a steady all-round performance. We delivered a healthy revenue growth accompanied by over 170bps YoY expansion in EBIDTA margin driven by favorable revenue mix and cost optimization initiatives. Our CDMO business continues to witness sustained order inflows, especially for on-patent commercial manufacturing. We are also...
PR Newswire
26/07/2024

Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary…

Ipsen receives CHMP positive opinions for Iqirvo ®(elafibranor) in Primary Biliary Cholangitis and Kayfanda ®(odevixibat) in Alagille Syndrome, two rare cholestatic liver diseasesCHMP positive opinion for Iqirvo ®(elafibranor) recommended for the treatment of primary biliary cholangitis, following FDA approval in June 2024CHMP positive opinion for Kayfanda ®(odevixibat) recommended for cholestatic pruritus in patients with Alagille syndrome...
Nasdaq GlobeNewswire
26/07/2024

Coagulation Testing Market to Reach USD 6.5 Billion by 2034: Surgical…

As the global population ages, there is a growing need for coagulation testing among the elderly population, who are at higher risk of thrombotic events and coagulation disorders, driving market expansion. Rapid economic development and improved healthcare infrastructure in emerging markets lead to greater accessibility to coagulation testing, fostering market growth and catering to previously underserved populations. As the global population ages, there is a growing need for coagulation...
PR Newswire
26/07/2024

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary…

The treatment groups were relatively well-balanced with no clinically relevant differences between the groups observed at baseline. The result is particularly encouraging as over 40% of the trial population was on dual therapy, ie was receiving UDCA (ursodeoxycholic acid) and either Ocaliva (obeticholic acid) or Bezafibrate (PPAR agonist) as base therapy and 13% were receiving all three therapies during the study, reflecting setanaxib having clinically relevant incremental benefit beyond…
PR Newswire
26/07/2024

S&P Global Ratings Reaffirms MAXIMA GRUPĖ, UAB BB+ Credit Rating with stable…

On July 25, 2024, following the review of group's operations and financial results, the international credit rating agency, has reaffirmed MAXIMA GRUPĖ's long-term issuer credit rating at BB+ with a stable outlook. S&P Global Ratings report highlights the group's revenue growth, successful expansion in Poland and Bulgaria, efficiently managed costs and stable cash flow generation.“We are pleased that S&P Global Ratings has recognized our strong performance in 2023, which exceeded...
Nasdaq GlobeNewswire
26/07/2024

Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world…

Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of the risk of mpox-related hospitalizationsCOPENHAGEN, Denmark, July 26, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a type II variation for IMVANEX ®(MVA-BN) smallpox and mpox vaccine, including real-world...
Nasdaq GlobeNewswire
26/07/2024
Altri  Comunicati